Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17402357 | ANTICOAGULANT COMPOUNDS AND METHODS AND DEVICES FOR THEIR USE | August 2021 | December 2022 | Allow | 60 | 2 | 2 | Yes | No |
| 17138703 | METHODS AND DEVICES FOR IN SITU FORMED NERVE CAP | December 2020 | May 2022 | Allow | 16 | 3 | 1 | Yes | No |
| 17057016 | STIMULATION OF THE YIELD OF ONE OR MORE DESIRED COMPOUNDS PRODUCED BY A PLANT | November 2020 | June 2024 | Abandon | 43 | 1 | 1 | No | No |
| 17096390 | Amorphous Silicon Oxide, Amorphous Silicon Oxynitride, and Amorphous Silicon Nitride Thin Films and Uses Thereof | November 2020 | June 2024 | Allow | 43 | 2 | 1 | Yes | No |
| 17077950 | POLYSACCHARIDE-POLYAMINE COPOLYMERS FOR REMOVAL OF PHOSPHATE | October 2020 | August 2024 | Allow | 46 | 1 | 1 | Yes | No |
| 17071102 | High Osmolarity Antimicrobial Composition Containing One or More Organic Solvents | October 2020 | August 2024 | Allow | 46 | 2 | 0 | No | No |
| 17069557 | ORAL TAXANE COMPOSITIONS AND METHODS | October 2020 | December 2023 | Allow | 38 | 5 | 0 | No | No |
| 17065727 | DRUG-IMPREGNATED ENCASEMENT | October 2020 | March 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17037830 | NANOCOMPOSITES, METHODS OF MAKING SAME, AND APPLICATIONS OF SAME FOR MULTICOLOR SURFACE ENHANCED RAMAN SPECTROSCOPY (SERS) DETECTIONS | September 2020 | August 2024 | Allow | 46 | 3 | 0 | Yes | No |
| 17015700 | EXPANDABLE GASTRORETENTIVE DOSAGE FORM | September 2020 | January 2023 | Allow | 28 | 4 | 1 | Yes | No |
| 16966111 | BIOINK COMPOSITION FOR CARTILAGE REGENERATION, METHOD FOR MANUFACTURING CUSTOMIZED SCAFFOLD FOR CARTILAGE REGENERATION USING SAME, AND CUSTOMIZED SCAFFOLD FOR CARTILAGE REGENERATION MANUFACTURED USING MANUFACTURING METHOD | July 2020 | February 2024 | Abandon | 43 | 2 | 1 | No | No |
| 16940740 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTIEMETICS AND ALPHA-2-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USING THE SAME FOR ANESTHESIOLOGICAL APPLICATIONS | July 2020 | October 2023 | Abandon | 38 | 2 | 1 | No | No |
| 16931034 | Transcutaneous Intraosseous Devices and Methods for Manufacturing Thereof | July 2020 | September 2023 | Abandon | 38 | 1 | 1 | No | No |
| 16927845 | BONE GRAFT COMPOSITION AND MANUFACTURING METHOD THEREOF | July 2020 | February 2025 | Allow | 55 | 5 | 1 | Yes | No |
| 16960379 | COLLAGEN PEPTIDE-CONTAINING POLYCAPROLACTONE MICROSPHERE FILLER AND PREPARATION METHOD THEREFOR | July 2020 | June 2025 | Abandon | 59 | 4 | 1 | No | No |
| 16918673 | IMPLANTS HAVING A DRUG LOAD OF AN OXYSTEROL AND METHODS OF USE | July 2020 | August 2021 | Allow | 14 | 2 | 0 | No | No |
| 16915025 | Active Agent Loaded Uniform, Rigid, Spherical, Nanoporous Calcium Phosphate Particles and Methods of Making and Using the Same | June 2020 | November 2023 | Abandon | 41 | 2 | 1 | No | No |
| 16899363 | GROWTH FACTOR TRANSDUCED CELL-LOADED CERAMIC SCAFFOLD FOR BONE REGENERATION AND REPAIR | June 2020 | July 2024 | Allow | 50 | 4 | 1 | No | No |
| 16770091 | FIBER BUNDLE REINFORCED BIOCOMPOSITE MEDICAL IMPLANTS | June 2020 | May 2025 | Abandon | 60 | 5 | 0 | No | No |
| 16887478 | OSTEOIMPLANT COMPRISING AN INSOLUBLE FIBROUS POLYMER | May 2020 | June 2025 | Abandon | 60 | 7 | 0 | No | No |
| 16882868 | NOVEL OCCLUSIVE FORMULATIONS | May 2020 | November 2021 | Allow | 18 | 1 | 0 | Yes | No |
| 16765977 | COMPOSITIONS AND METHODS FOR ADMINISTERING A YAP1/WWRT1 INHIBITING COMPOSITION AND A GLS1 INHIBITING COMPOSITION | May 2020 | September 2023 | Abandon | 40 | 3 | 1 | No | No |
| 16874313 | 3D-Porous Hybrid Anti-Inflammatory Nanoscaffold for Drug Delivery and Tissue Engineering | May 2020 | March 2025 | Allow | 58 | 6 | 1 | Yes | No |
| 16763753 | SYSTEMS AND METHODS FOR RECONSTRUCTION OF NERVE DEFECTS | May 2020 | November 2022 | Allow | 30 | 2 | 0 | No | No |
| 16868178 | LYOPHILIZED MOLDABLE IMPLANTS CONTAINING AN OXYSTEROL | May 2020 | December 2020 | Allow | 7 | 1 | 0 | Yes | No |
| 16864373 | DRUG COATED BALLOON CATHETERS FOR NONVASCULAR STRICTURES | May 2020 | December 2021 | Abandon | 19 | 2 | 1 | Yes | No |
| 16863836 | THERMALLY NEUTRAL INHALATION GAS COMPOSITION | April 2020 | September 2022 | Abandon | 29 | 2 | 0 | Yes | No |
| 16850037 | Systems And Methods For Delivering Active Agents | April 2020 | May 2022 | Abandon | 25 | 1 | 1 | Yes | No |
| 16755811 | INJECTABLE AND EXPANDABLE COMPOSITION, DEVICES, KITS, METHODS AND USES THEREOF | April 2020 | September 2021 | Allow | 17 | 0 | 0 | Yes | No |
| 16652357 | EYE MAKE-UP COSMETIC COMPOSITION COMPRISING ACRYLATE-BASED COPOLYMER | March 2020 | May 2022 | Abandon | 25 | 3 | 1 | No | No |
| 16650555 | PARTICLE SUITABLE FOR THE MANUFACTURE OF AN IMPLANTABLE SOFT TISSUE ENGINEERING MATERIAL | March 2020 | June 2022 | Allow | 26 | 2 | 1 | Yes | No |
| 16795174 | Fast Acting Inhibitor of Gastric Acid Secretion | February 2020 | May 2022 | Abandon | 27 | 1 | 1 | No | No |
| 16793470 | VASCULAR GRAFT AND METHODS FOR SEALING A VASCULAR GRAFT | February 2020 | July 2024 | Abandon | 53 | 6 | 1 | Yes | No |
| 16789477 | RODENT REPELLING SPRAY POLYURETHANE FOAM SYSTEM | February 2020 | October 2021 | Abandon | 20 | 3 | 0 | No | No |
| 16780596 | UNIAXIALLY-ALIGNED NANOFIBER SCAFFOLDS AND METHODS FOR PRODUCING AND USING SAME | February 2020 | November 2024 | Allow | 58 | 5 | 1 | Yes | No |
| 16746460 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | January 2020 | December 2020 | Allow | 11 | 1 | 0 | No | No |
| 16743700 | SYSTEMS TO PROMOTE HEALING AT A SITE OF A MEDICAL DEVICE | January 2020 | November 2023 | Abandon | 46 | 3 | 1 | No | No |
| 16617415 | IONIC-DOPED COMPOSITION METHODS AND USES THEREOF | November 2019 | April 2023 | Abandon | 40 | 3 | 0 | No | No |
| 16602706 | Drug delivery system and method for the treatment of neuro-degenerative disease | November 2019 | October 2021 | Abandon | 23 | 1 | 0 | No | No |
| 16616418 | FORMATION OF STABLE CARTILAGE | November 2019 | October 2020 | Allow | 11 | 0 | 0 | Yes | No |
| 16687336 | High Osmolarity Antimicrobial Composition Containing One or More Organic Solvents | November 2019 | September 2021 | Allow | 22 | 1 | 1 | Yes | No |
| 16686128 | High Osmolarity Antimicrobial Composition Containing One or More Organic Solvents | November 2019 | September 2021 | Allow | 22 | 1 | 1 | No | No |
| 16614089 | MEDICAL DEVICE WITH DRUG-ELUTING COATING AND INTERMEDIATE LAYER | November 2019 | August 2024 | Abandon | 57 | 4 | 1 | Yes | No |
| 16683951 | FUNCTIONALIZED NANOPARTICLES HAVING ENCAPSULATED GUEST CARGO AND METHODS FOR MAKING THE SAME | November 2019 | August 2023 | Allow | 45 | 4 | 1 | Yes | No |
| 16666987 | IMPLANTABLE THERAPEUTIC DELIVERY SYSTEM HAVING A NANOFIBROUS CORE | October 2019 | September 2023 | Allow | 47 | 3 | 1 | No | No |
| 16665622 | BUCCAL, POLAR AND NON-POLAR SPRAY CONTAINING ZOLIPIDEM | October 2019 | March 2021 | Abandon | 17 | 2 | 0 | No | No |
| 16660936 | NERVE REPAIR CONDUITS INCORPORATING SILICA FIBERS | October 2019 | February 2024 | Allow | 52 | 2 | 1 | No | No |
| 16606585 | PLASMA IMMOBILIZATION OF BACTERIOPHAGES AND APPLICATIONS THEREOF | October 2019 | January 2022 | Allow | 27 | 3 | 1 | Yes | No |
| 16497637 | METHOD FOR PRODUCING ANTIBACTERIAL BIOLOGICAL IMPLANT | September 2019 | December 2020 | Allow | 15 | 1 | 0 | Yes | No |
| 16553651 | RESORBABLE NONWOVEN POUCHES FOR MEDICAL DEVICE IMPLANTS | August 2019 | November 2022 | Allow | 39 | 2 | 1 | Yes | No |
| 16552890 | TA2O5 AND TA2O5 - TIO2 HYBRID SURFACES FOR INVASIVE SURGICAL DEVICES | August 2019 | August 2022 | Abandon | 36 | 0 | 1 | No | No |
| 16550931 | MEDICAL GLASS ELEMENT | August 2019 | April 2023 | Abandon | 44 | 6 | 0 | Yes | No |
| 16549420 | IMPLANT, DIAGNOSIS AND TREATMENT DEVICE, AND METHOD OF EMITTING LASER | August 2019 | January 2024 | Abandon | 53 | 2 | 1 | No | No |
| 16540910 | Biodegradable Wire Implant | August 2019 | June 2023 | Abandon | 46 | 1 | 1 | No | No |
| 16483420 | PROCESS FOR INSTANT NANOPOROUS BIOARTIFICIAL BONE TISSUE COMPOSITE ENGINEERING | August 2019 | August 2021 | Abandon | 25 | 0 | 1 | No | No |
| 16474597 | ASSEMBLY COMPRISING A RESORBABLE MATERIAL HAVING ANTIBACTERIAL ACTIVITY | June 2019 | November 2022 | Allow | 40 | 1 | 0 | No | No |
| 16457517 | SYSTEMS TO PROMOTE HEALING AT A SITE OF A MEDICAL DEVICE | June 2019 | November 2019 | Allow | 5 | 0 | 0 | Yes | No |
| 16450076 | EXPANDABLE GASTRORETENTIVE DOSAGE FORM | June 2019 | November 2021 | Allow | 29 | 2 | 0 | Yes | No |
| 16424543 | IMPLANT COMPRISING OXIDIZED CELLULOSE AND METHOD FOR PREPARING SUCH AN IMPLANT | May 2019 | January 2020 | Allow | 7 | 1 | 0 | Yes | No |
| 16374089 | DRUG DELIVERY DEVICE AND METHOD | April 2019 | January 2024 | Abandon | 58 | 4 | 1 | Yes | Yes |
| 16337893 | GROWTH FACTOR TRANSDUCED CELL-LOADED CERAMIC SCAFFOLD FOR BONE REGENERATION AND REPAIR | March 2019 | February 2024 | Allow | 59 | 3 | 1 | Yes | No |
| 16337287 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | March 2019 | May 2021 | Abandon | 26 | 0 | 1 | No | No |
| 16334382 | POROUS COMPOSITE MATERIAL | March 2019 | July 2022 | Allow | 40 | 2 | 1 | Yes | No |
| 16294971 | METHOD FOR RELIEVING SINUS CONGESTION | March 2019 | October 2019 | Allow | 8 | 1 | 0 | No | No |
| 16290727 | ORIENTED IMPLANTS CONTAINING POLY(BUTYLENE SUCCINATE) AND COPOLYMER, AND METHODS OF USE THEREOF | March 2019 | September 2023 | Allow | 54 | 4 | 1 | Yes | No |
| 16278092 | ANTIMICROBIAL INVASIVE SURGICAL DEVICES AND SYSTEMS | February 2019 | January 2022 | Abandon | 35 | 1 | 1 | No | No |
| 16271475 | IMPLANTS HAVING A DRUG LOAD OF AN OXYSTEROL AND METHODS OF USE | February 2019 | October 2019 | Allow | 8 | 1 | 0 | Yes | No |
| 16267434 | DRUG COATED BALLOON CATHETERS FOR NONVASCULAR STRICTURES | February 2019 | April 2020 | Allow | 14 | 4 | 0 | No | No |
| 16319927 | USE OF THERMOLYSIN TO REDUCE OR ELIMINATE BACTERIAL BIOFILMS FROM SURFACES | January 2019 | December 2022 | Allow | 47 | 3 | 1 | No | No |
| 16319717 | MEDICINAL COMPOSITION FOR IMPROVING AND/OR STABILIZING CIRCULATORY DYNAMICS AFTER ONSET OF HEMORRHAGIC SHOCK | January 2019 | October 2022 | Abandon | 45 | 4 | 0 | Yes | No |
| 16252931 | TREATMENT OF EXCESSIVE MENSTRUAL BLOOD LOSS BY FEMININE SANITARY PRODUCTS MEDICATED WITH HEMOSTATIC AGENT | January 2019 | March 2021 | Abandon | 26 | 3 | 0 | No | No |
| 16250304 | AMNIOTIC OR PLACENTAL PREPARATION AND DEVICE FOR OPHTHALMIC USE AS DRESSING TO ENHANCE HEALING | January 2019 | August 2022 | Abandon | 43 | 3 | 0 | Yes | Yes |
| 16318308 | EXTENDED RELEASE DOSAGE FORMS OF PREGABALIN | January 2019 | February 2021 | Allow | 25 | 3 | 0 | No | No |
| 16312680 | MAGNETICALLY-ACTIVATED COATING FOR TREATING BIOFILMS, AND ASSOCIATED SYSTEMS AND METHODS | December 2018 | June 2024 | Allow | 60 | 4 | 1 | No | No |
| 16220370 | High SPF, Photo-protective Zinc Oxide Sunscreen Emulsions | December 2018 | February 2021 | Abandon | 26 | 1 | 0 | No | No |
| 16213574 | Naloxone Transdermal Delivery Devices and Methods for Using the Same | December 2018 | September 2023 | Abandon | 57 | 7 | 0 | No | No |
| 16209587 | COSMETIC COMPOSITION FOR TREATMENT OF KERATINOUS FIBERS | December 2018 | June 2022 | Abandon | 43 | 4 | 1 | Yes | No |
| 16171470 | Biomaterial Implant | October 2018 | July 2021 | Abandon | 33 | 2 | 1 | No | No |
| 16091147 | THERMALLY NEUTRAL INHALATION GAS COMPOSITION | October 2018 | September 2020 | Abandon | 23 | 2 | 0 | Yes | No |
| 16151774 | IMPLANTABLE FUSION DEVICES COMPRISING BIOACTIVE GLASS | October 2018 | October 2022 | Abandon | 48 | 3 | 0 | No | No |
| 16148289 | BIOACTIVE IMPLANTS AND METHODS OF MAKING AND USING | October 2018 | December 2019 | Allow | 15 | 2 | 0 | No | No |
| 16146407 | Transdermal Delivery of Selexipag Metabolite | September 2018 | January 2021 | Abandon | 28 | 1 | 1 | No | No |
| 16089613 | NOVEL BONE PUTTY COMPOSITIONS AND METHODS OF USE THEREOF | September 2018 | February 2022 | Abandon | 40 | 1 | 1 | No | No |
| 16137714 | FAST ACTING INHIBITOR OF GASTRIC ACID SECRETION | September 2018 | November 2019 | Allow | 14 | 2 | 0 | No | No |
| 16085969 | ANTI-FOULING AND/OR ANTI-THROMBOTIC MEDICAL DEVICES | September 2018 | September 2020 | Allow | 24 | 2 | 0 | No | No |
| 16130860 | BUCCAL, POLAR AND NON-POLAR SPRAY CONTAINING ZOLIPIDEM | September 2018 | February 2020 | Abandon | 17 | 2 | 0 | Yes | No |
| 16128784 | COMPOSITIONS FOR TREATING BONE DEFECTS | September 2018 | June 2019 | Allow | 9 | 1 | 0 | Yes | No |
| 16109153 | TRIZONAL MEMBRANES FOR PERIOSTEUM REGENERATION | August 2018 | November 2021 | Abandon | 38 | 1 | 1 | No | No |
| 16107547 | SOLID FORMS FOR TISSUE REPAIR | August 2018 | January 2021 | Abandon | 29 | 1 | 1 | No | No |
| 16048658 | Solid Forms For Tissue Repair | July 2018 | March 2020 | Allow | 19 | 2 | 0 | Yes | No |
| 16039317 | STERILIZING AGENTS, THEIR METHOD OF MANUFACTURE AND USES | July 2018 | April 2021 | Allow | 33 | 2 | 1 | Yes | No |
| 16070574 | TRANSDERMAL PATCH | July 2018 | June 2021 | Abandon | 35 | 3 | 0 | No | No |
| 16019258 | Active Agent Loaded Uniform, Rigid, Spherical, Nanoporous Calcium Phosphate Particles and Methods of Making and Using the Same | June 2018 | March 2020 | Allow | 21 | 2 | 0 | No | No |
| 16014908 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | June 2018 | September 2019 | Allow | 15 | 1 | 0 | Yes | No |
| 16004352 | ANTIBIOTIC-LOADED TRANSDERMAL PATCH | June 2018 | June 2019 | Allow | 12 | 1 | 0 | No | No |
| 15775137 | IRON-BASED ALLOY ABSORBABLE AND IMPLANTABLE MEDICAL DEVICE FOR INTERNAL FIXATION | May 2018 | June 2023 | Allow | 60 | 5 | 0 | Yes | No |
| 15976806 | High Osmolarity Antimicrobial Composition Containing One or More Organic Solvents | May 2018 | July 2019 | Allow | 60 | 1 | 0 | No | No |
| 15971556 | Liquid Termiticide Compositions of Pyrethroids and Neonicitinoids | May 2018 | November 2018 | Allow | 6 | 1 | 0 | No | No |
| 15755374 | Implantable Naltrexone Tablets | May 2018 | May 2019 | Allow | 14 | 1 | 0 | No | No |
| 15965340 | Hard Capsule Shell Compositions for the Treatment of Irritable Bowel Syndrome | April 2018 | August 2020 | Abandon | 27 | 2 | 0 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HAGOPIAN, CASEY SHEA.
With a 8.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 16.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HAGOPIAN, CASEY SHEA works in Art Unit 1617 and has examined 509 patent applications in our dataset. With an allowance rate of 58.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner HAGOPIAN, CASEY SHEA's allowance rate of 58.5% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HAGOPIAN, CASEY SHEA receive 2.26 office actions before reaching final disposition. This places the examiner in the 59% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by HAGOPIAN, CASEY SHEA is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +40.6% benefit to allowance rate for applications examined by HAGOPIAN, CASEY SHEA. This interview benefit is in the 87% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 22.7% of applications are subsequently allowed. This success rate is in the 33% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 40.5% of cases where such amendments are filed. This entry rate is in the 63% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 44.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 40% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 60.0% of appeals filed. This is in the 35% percentile among all examiners. Of these withdrawals, 61.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 64.1% are granted (fully or in part). This grant rate is in the 67% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.2% of allowed cases (in the 51% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.7% of allowed cases (in the 74% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.